KeyCorp restated their buy rating on shares of Hill-Rom Holdings Inc (NYSE:HRC) in a report issued on Tuesday morning. They currently have a $82.00 price objective on the medical technology company’s stock.

A number of other equities research analysts have also weighed in on HRC. Cantor Fitzgerald started coverage on shares of Hill-Rom Holdings in a report on Thursday, June 29th. They issued a neutral rating and a $86.00 price objective on the stock. Needham & Company LLC initiated coverage on shares of Hill-Rom Holdings in a research report on Thursday, June 29th. They issued a buy rating and a $95.00 target price on the stock. Morgan Stanley increased their target price on shares of Hill-Rom Holdings from $85.00 to $90.00 and gave the company an overweight rating in a research report on Friday, June 30th. Zacks Investment Research downgraded shares of Hill-Rom Holdings from a buy rating to a hold rating in a research report on Tuesday, July 11th. Finally, BidaskClub downgraded shares of Hill-Rom Holdings from a strong-buy rating to a buy rating in a research report on Monday, July 24th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has an average rating of Buy and an average target price of $86.83.

Hill-Rom Holdings (NYSE HRC) traded up 1.11% during trading on Tuesday, reaching $81.19. 431,871 shares of the company’s stock traded hands. Hill-Rom Holdings has a 12-month low of $50.50 and a 12-month high of $84.65. The company has a 50 day moving average price of $76.25 and a 200-day moving average price of $76.39. The company has a market cap of $5.35 billion, a PE ratio of 47.31 and a beta of 1.19.

Hill-Rom Holdings (NYSE:HRC) last announced its quarterly earnings data on Friday, July 28th. The medical technology company reported $0.91 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.90 by $0.01. Hill-Rom Holdings had a net margin of 4.27% and a return on equity of 19.99%. The business had revenue of $689.10 million for the quarter, compared to analyst estimates of $695.50 million. During the same period last year, the business earned $0.81 EPS. The company’s revenue was up 5.1% on a year-over-year basis. On average, equities research analysts forecast that Hill-Rom Holdings will post $3.82 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.watchlistnews.com/hill-rom-holdings-hrc-buy-rating-reiterated-at-keycorp/1644027.html.

In other news, SVP Andreas G. Frank sold 3,940 shares of Hill-Rom Holdings stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $77.84, for a total value of $306,689.60. Following the sale, the senior vice president now owns 16,701 shares of the company’s stock, valued at $1,300,005.84. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Andreas G. Frank sold 6,870 shares of Hill-Rom Holdings stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $77.48, for a total transaction of $532,287.60. Following the completion of the sale, the senior vice president now directly owns 16,701 shares in the company, valued at approximately $1,293,993.48. The disclosure for this sale can be found here. Company insiders own 2.20% of the company’s stock.

Large investors have recently modified their holdings of the company. Independent Portfolio Consultants Inc. boosted its holdings in shares of Hill-Rom Holdings by 171.5% in the second quarter. Independent Portfolio Consultants Inc. now owns 1,344 shares of the medical technology company’s stock valued at $107,000 after acquiring an additional 849 shares in the last quarter. Seven Eight Capital LP purchased a new stake in shares of Hill-Rom Holdings in the second quarter valued at about $127,000. Acrospire Investment Management LLC boosted its holdings in shares of Hill-Rom Holdings by 43.4% in the second quarter. Acrospire Investment Management LLC now owns 1,983 shares of the medical technology company’s stock valued at $158,000 after acquiring an additional 600 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Hill-Rom Holdings by 10.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,201 shares of the medical technology company’s stock valued at $175,000 after acquiring an additional 204 shares in the last quarter. Finally, Citigroup Inc. boosted its holdings in shares of Hill-Rom Holdings by 21.1% in the second quarter. Citigroup Inc. now owns 2,483 shares of the medical technology company’s stock valued at $198,000 after acquiring an additional 433 shares in the last quarter. 82.31% of the stock is currently owned by institutional investors and hedge funds.

About Hill-Rom Holdings

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Analyst Recommendations for Hill-Rom Holdings (NYSE:HRC)

Receive News & Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.